http://purl.org/np/RAQpp12qzk... RAQpp12qzk

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-13T13:46:07.779Z

http://purl.org/np/RAQpp12qzk... RAQpp12qzk

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-13T13:46:07.779203

Elif Ozkan

2022-10-13T13:46:07.779Z

http://purl.org/np/RAQpp12qzk... RAQpp12qzk

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing. This combination regimen is also used for post-exposure prophylaxis of COVID-2019 in unvaccinated or immunocompromised adults.

Elif Ozkan

2022-10-13T13:46:07.779Z